Research · Sep 3, 2026
[GMED] Globus Medical Thesis 2026: Spine Trauma Cycle Drives NuVasive Integration Margin Recovery
Globus Medical Inc. (NYSE: GMED) FY2025 revenue ~$2.55-2.75B (+5-12%) with adj. EPS ~$3.20-3.55 reflecting continued post-2024 ~$2.0-2.15B aggregate Musculoskeletal Solutions revenue (~78%+ aggregate revenue mix; selected primary spine + selected various trauma) + selected continued post-2024 ~$540-620M aggregate Enabling Technologies revenue (~22% aggregate revenue mix; selected primary ExcelsiusGPS + selected various robotic surgery + selected various imaging) + selected continued post-September 2023 ~$3.1B aggregate NuVasive merger completion + selected various NuVasive integration synergies (~$220-280M aggregate cumulative cost synergies) under continued President + CEO Daniel Scavilla since 2020 (~5-year tenure as Globus Medical CEO). One of the largest US musculoskeletal solutions + spine + trauma + robotic surgery medical device companies. Founded 2003 as Globus Medical in King of Prussia Pennsylvania by David Paul + selected various spine surgeon co-founders (~22-year heritage); selected post-August 2012 NYSE listing IPO; selected post-2017 ExcelsiusGPS robotic surgery FDA approval; selected post-2020 Daniel Scavilla CEO appointment; selected post-September 2023 ~$3.1B aggregate NuVasive Inc. merger completion. Headquartered in Audubon Pennsylvania; ~4,000+ employees globally with ~$2.55-2.75B revenue. Two primary business segments: Musculoskeletal Solutions (~78%+ ~$2.0-2.15B), Enabling Technologies (~22% ~$540-620M). Geographic mix: US ~80%+ + International ~20%. Spine + trauma cycle: selected primary US spine + trauma + extremities + selected various Musculoskeletal Solutions market leadership. Enabling Technologies + ExcelsiusGPS: ExcelsiusGPS + ExcelsiusHub + ExcelsiusFlex robotic surgery + imaging. President + CEO Daniel Scavilla since 2020 (~5-year tenure); CFO Keith Pfeil. Capital return + NuVasive integration: post-September 2023 ~$3.1B aggregate NuVasive merger; ~$220-280M aggregate cumulative cost synergies; ~$0M dividend FY2025 (selected primary capital deployment for NuVasive integration + tuck-in M&A); ~$200-400M aggregate FY2024-2025 buyback program (~$100-200M aggregate FY2025); aggregate capital return ~$100-200M; net leverage ratio ~1.0-1.4x; ~$0.6-0.8B aggregate cash + investments balance; investment-grade pathway pre-credit-rating. FY2026 thesis: Spine + trauma cycle + Enabling Technologies + ExcelsiusGPS robotic surgery adoption + selected post-September 2023 NuVasive merger integration synergies + ~$0.6-0.9B aggregate cash + investments balance + ~1.0-1.4x net leverage + ~$100-300M aggregate annual buybacks + selected pathway to dividend initiation FY2026-2027. Risks: Stryker + Zimmer Biomet + Medtronic + JNJ DePuy Synthes competition, US spine cycle, NuVasive integration execution, ExcelsiusGPS robotic surgery adoption sustainability, US payer + reimbursement risk.